Charles M. Noyer MD, Director of Gastroenterology and Joshua Raff MD, Director of the Digestive Cancer Program, and their efforts to promote a Pancreatic Cancer Screening Awareness Campaign.
ReMission Foundation, with the support of White Plains Hospital Cancer Center, is pleased to support Charles M. Noyer MD, Director of Gastroenterology and Joshua Raff MD, Director of the Digestive Cancer Program, and their efforts to promote a Pancreatic Cancer Screening Awareness Campaign.
In 2023, 64,000 adults in the US were diagnosed with pancreatic cancer, of which 80% are diagnosed at an advanced stage and are ineligible for surgery. Unfortunately, even after surgery, relapses are common and five-year survival is typically only 10-30%. Given these challenging outcomes, White Plains Hospital recognized the need to develop a screening program for individuals at an elevated risk for pancreatic cancer. In 2014, Drs. Joshua Raff, Director of the Digestive Cancer Program, and Charles Noyer, Director of Gastroenterology, introduced a clinical trial in line with the National Comprehensive Cancer Network Guidelines for Pancreatic Cancer Screening to screen individuals at higher risk. The trial, which ran over a 10-year period, reported successful outcomes. As a result of the trial’s success, the Wolters Kluwer journal Pancreas published the trial’s manuscript in the following article Successful Pancreatic Cancer Screening Among Individuals at Elevated Risk Using Endoscopic Ultrasound and Magnetic Resonance Imaging.
ReMission Foundation and White Plains Hospital have partnered to spearhead a campaign focused on increasing awareness of the importance of pancreatic cancer screening, educate on risk factors and encourage screening for those at elevated risk. The target audience for the awareness campaign is adults beginning at age 40 with a family history of and/or a genetic disposition to pancreatic cancer within the Westchester, Rockland, and Greenwich regions.